Genentech Announces Positive Phase II Results for Petrelintide, an Amylin Analog Developed for People Living With Overweight and Obesity

Core Insights - Genentech announced positive Phase II results for petrelintide, an amylin analog, showing a mean body weight reduction of up to 10.7% at week 42 compared to 1.7% with placebo, with a p-value of less than 0.001 [1][2] - The trial demonstrated that petrelintide has a favorable tolerability profile, with no cases of vomiting at the maximally effective dose and a treatment discontinuation rate of 4.8% compared to 4.9% for placebo [1][2] - The study involved 493 participants with a mean BMI of 37 kg/m², and the results support further development of petrelintide for chronic weight management [1][2] Study Details - The Phase II ZUPREME-1 trial was randomized, double-blind, and placebo-controlled, lasting 42 weeks, with participants receiving once-weekly subcutaneous injections of petrelintide [1][2] - The primary endpoint was the percentage change in body weight from baseline to week 28, with secondary endpoints including changes in waist circumference, HbA1c, hsCRP, fasting lipids, and fasting glucose [2] - The trial population was gender-balanced, with 53% female participants, and included a dose escalation period followed by a maintenance period [1][2] Future Developments - Final data from the ZUPREME-1 trial, including a nine-week safety follow-up, will be presented at an upcoming medical congress [1] - Topline results from a second Phase II trial, ZUPREME-2, are expected in the second half of 2026, focusing on individuals with obesity or overweight and type 2 diabetes [1] - A Phase II trial exploring the combination of petrelintide and CT-388 will be initiated later in 2026 [1] Market Context - Obesity is identified as the greatest single risk factor for chronic disease globally, with projections indicating over four billion people will be living with overweight and obesity by 2035 [1] - Genentech and Roche entered into a collaboration with Zealand to co-develop and commercialize petrelintide, addressing the growing need for effective obesity treatments [1][2]